1 / 32

Ivowen Limited

Ivowen Limited. Preparation and Submission of a Traditional Herbal Medicinal Product Application. Directive 2004/24/EC. Traditional Herbal Medicinal Products Directive 2004/24/EC introduces a simplified registration procedure for traditional herbal medicinal products.

hamish
Download Presentation

Ivowen Limited

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application Ivowen Ltd

  2. Directive 2004/24/EC • Traditional Herbal Medicinal Products Directive 2004/24/EC introduces a simplified registration procedure for traditional herbal medicinal products. • This directive was transposed into Irish law – (SI No. 540 of 2007) on 23 July 2007. • IMB established a Traditional Herbal Medicines Products Registration Scheme. • An applicant can apply for a certificate of traditional-use registration for a THMP. This registration is called a traditional-use registration. Ivowen Ltd

  3. National Regulation • No medicinal product can be placed on the market without a prior MA (marketing authorisation) or certificate of traditional-use registration. • The regulation however provides an exemption until 30th April 2011 for THMP already on the market prior to the regulations coming into force. • However IMB can request that applicants apply for a certificate of traditional-use registration before this date e.g. January 2010. Ivowen Ltd

  4. First Steps Before Submission • Familiarise yourself with EU legislation, Notice to Applicants, IMB guidance and HMPC guidance. • Be sure that your product fulfils the criteria of a traditional herbal medicinal product. • Prepare the documentation in the correct format and address all modules (where applicable). • Obtain a company number and a product number (e.g. TR/xx/yy/zz) from The Receipts and Validation Section, IMB. Ivowen Ltd

  5. Dossier Format • Format of dossier is Common Technical Document (CTD). • Guidance available specific for Herbals. • The CTD is organised into five modules. Ivowen Ltd

  6. CTD structure Ivowen Ltd

  7. CTD structure • Common Technical Document (CTD) Module 1: Administrative Information Module 2: CTD Summaries Module 3: Quality Module 4: Non-clinical Study Reports Module 5: Clinical Study Reports • Each Module should be bound separately. Ivowen Ltd

  8. Module 1 • Module 1.1 – Comprehensive table of contents (Modules 1 – 5) • Module 1.2 – Application form • Module 1.3 – Product Information • 1.3.1 – Summary of Product Characteristics, Labelling and Leaflet • 1.3.2 – Mock-Up • 1.3.3 – Specimen (NOT REQUIRED) • 1.3.4 – Consultation with target patient groups • 1.3.5 – SmPCs- already approved in Member States • 1.3.6 – Braille Ivowen Ltd

  9. Module 1 • Module 1.4 - Information about the experts -1.4.1 Quality -1.4.2 Non-Clinical -1.4.3 Clinical • Module 1.5 - Specific requirements for different types of applications Ivowen Ltd

  10. Module 1.2Application Form • The application form for a certificate of traditional-use registration in Ireland is the EU application Form. http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/b/update_2007-03/applicformrevised_final.pdf • Summary of information required to complete form: • Product name + strength + form • Proposed Applicant/Marketing Authorisation Holder • Pharmacovigilance contact • Manufacturer of Substance + Product (including manufacturers authorisations) Ivowen Ltd

  11. Module 1.3.1Product Information • SmPC • As per Directive 2001/83/EC, Art. 11, as amended. • Includes the name, strength, form, quantity of active, posology, method of administration, indications, contraindications, excipients, shelf life and any special warnings and precautions for use (section 1-4). Section 5 is not usually required. Ivowen Ltd

  12. Module 1.3.1Product Information • Labelling & Package Leaflet • Directive 2001/83/EC, Art 54 – 69, as amended. • The package leaflet should be drawn up inaccordance with the Summary of Product Characteristics (SmPC). • Mock-ups (label/carton & Package leaflet) must be provided before final approval will be given. Ivowen Ltd

  13. Module 1.3.4Consultation with Target Patient Groups • Directive 2001/83/EC, Art 59-61, as amended. • Introduction of ‘user-testing’ to ensure that leaflets are easy to read and can be understood by the patient (patient-friendly language). Ivowen Ltd

  14. Module 1.3.6Braille • Directive 2001/83/ECArticle 56 states that the name of the medicinal product should be expressed in Braille format on the packaging.  • You should include here the proposed braille text (in normal font) which will be printed on the outer carton along with the actual braille which is indicated with dots on the mock-ups.  • IMB request an additional braille statement to be included in this section. Ivowen Ltd

  15. Module 1. 4Information about the Experts • 1.4.1 Quality • Signature page along with CV from expert who prepared Module 2.3. • 1.4.2 Non-Clinical • Signature page along with CV from expert who prepared Module 2.4. • 1.4.3 Clinical • Signature page along with CV from expert who prepared Module 2.5. Ivowen Ltd

  16. Module 1.5Specific Requirements • A brief summary/paragraph stating how this application meets the requirements for a traditional-use registration. Ivowen Ltd

  17. Module 2 • Module 2.1 CTD Table of Contents • Module 2.2 Introduction • Module 2.3 Quality Overall Summary • Module 2.4 Nonclinical Overview • Module 2.5 Clinical Overview • Module 2.6 Nonclinical Summary • Module 2.7 Clinical Summary Ivowen Ltd

  18. Module 2.3 • Summary of Module 3. • Cannot have additional data not already presented in Module 3. • Sufficient information to provide assessor with complete overview of Module 3. • Not more than 40 pages of text. • Prescribed layout. Ivowen Ltd

  19. Module 2.4 • Summary of Module 4. • Integrated and critical assessment of safety data of proposed product. • Expert compiling this report must have appropriate experience and qualifications. Ivowen Ltd

  20. Module 2.5 • Summary of Module 5. • The bibliographic or expert evidence of traditional-use (proof that the traditional herbal medicinal product or a corresponding product has been in medicinal use for at least 30 years (15 years must be in the EU) should be discussed. Ivowen Ltd

  21. Module 3 • Drug substance – 3.2.S • Drug product – 3.2.P • Regional information – 3.2.R • Literature references – 3.3 Ivowen Ltd

  22. Module 3.2.S • Drug substance – 3.2.S • 3.2.S.1 General information • 3.2.S.2 Manufacture • 3.2.S.3 Characterization • 3.2.S.4 Control of drug substance • 3.2.S.5 Reference standards or materials • 3.2.S.6 Container closure system • 3.2.S.7 Stability Ivowen Ltd

  23. Module 3.2.P • Drug product – 3.2.P • 3.2.P.1 Description and composition of the drug product • 3.2.P.2 Pharmaceutical development • 3.2.P.3 Manufacture • 3.2.P.4 Control of excipients • 3.2.P.5 Control of drug product • 3.2.P.6 Reference standards or materials • 3.2.P.7 Container closure system • 3.2.P.8 Stability Ivowen Ltd

  24. Module 3.2.A • Facilities and equipment – biotech only. • Adventitious agents safety evaluation. • TSE is most common entry in this section • Novel excipients. Ivowen Ltd

  25. Module 3.2.R • Process validation scheme for the 3 consecutive production batches. • Certificates of Suitability of Monographs of the European Pharmacopoeia. • TSE certificates of suitability together with completed Table A on ‘Materials of animal origin’. Ivowen Ltd

  26. Module 3.3 Literature references • Any literature references used throughout the completion of Module 3 should be included in this section. Ivowen Ltd

  27. Module 3-Summary • In assembling the dossier for traditional-use registrations the applicant needs to take into account the scientific guidelines adopted by the CHMP/HCMP/Commission. • Applicants need to be aware of all guidelines both general and specific and keep up to date with any revisions to guidance documents. • European Pharmacopoeia standards are legally binding. Ivowen Ltd

  28. Module 4Safety • Module 4.1 Introduction • Module 4.2 Study Reports • Module 4.3 Literature References • The bibliographic review should cover all safety aspects and should refer to a review of literature references and relevant published scientific literature. • More data may be requested in order to assess the safety of the product. • If the herbal substance (preparation/combination) is on the ‘list’, the data do not need to be provided. Ivowen Ltd

  29. Module 5Traditional-Use • 5.1 Module 5 Table of Contents • 5.2 Tabular Listing of All Clinical Studies • 5.3. Clinical Study Reports • 5.4 Literature References • Applicants should produce bibliographic or expert evidence documenting the traditional-use of the product for the proposed indication. • Evidence of use may be based on a similar product (same actives, strength, posology). Ivowen Ltd

  30. Final Steps • Ensure that each Module is bound separately, each section is clearly identified and each page is numbered. • Ensure the correct number of copies (Electronic and/or Paper) is submitted. • Ensure the correct fees are paid. • Ensure the application is delivered to the correct address. Ivowen Ltd

  31. After Submission • An estimated 210 days to obtain a certificate of traditional-use registration. • Dependant on both the applicant and the agency. Ivowen Ltd

  32. Ivowen Limited • Any questions?? Ivowen Ltd

More Related